CN1362955A - 作为抗肿瘤剂的c7酯取代的紫杉烷 - Google Patents

作为抗肿瘤剂的c7酯取代的紫杉烷 Download PDF

Info

Publication number
CN1362955A
CN1362955A CN01800306A CN01800306A CN1362955A CN 1362955 A CN1362955 A CN 1362955A CN 01800306 A CN01800306 A CN 01800306A CN 01800306 A CN01800306 A CN 01800306A CN 1362955 A CN1362955 A CN 1362955A
Authority
CN
China
Prior art keywords
pyridyl
furyl
thienyl
taxane
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01800306A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·霍尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Florida State University Research Foundation Inc
Original Assignee
Florida State University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florida State University Research Foundation Inc filed Critical Florida State University Research Foundation Inc
Publication of CN1362955A publication Critical patent/CN1362955A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN01800306A 2000-02-02 2001-02-02 作为抗肿瘤剂的c7酯取代的紫杉烷 Pending CN1362955A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17979400P 2000-02-02 2000-02-02
US60/179,794 2000-02-02

Publications (1)

Publication Number Publication Date
CN1362955A true CN1362955A (zh) 2002-08-07

Family

ID=22658029

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01800306A Pending CN1362955A (zh) 2000-02-02 2001-02-02 作为抗肿瘤剂的c7酯取代的紫杉烷

Country Status (35)

Country Link
US (3) US6610860B2 (enExample)
EP (1) EP1183253B8 (enExample)
JP (1) JP2003522167A (enExample)
KR (1) KR100784161B1 (enExample)
CN (1) CN1362955A (enExample)
AR (1) AR030188A1 (enExample)
AT (1) ATE396188T1 (enExample)
AU (1) AU776051B2 (enExample)
BG (1) BG65279B1 (enExample)
BR (1) BR0104749A (enExample)
CA (1) CA2368993C (enExample)
CO (1) CO5280224A1 (enExample)
CZ (1) CZ298484B6 (enExample)
DE (1) DE60134094D1 (enExample)
DK (1) DK1183253T3 (enExample)
ES (1) ES2307588T3 (enExample)
GE (1) GEP20043322B (enExample)
HK (1) HK1047938A1 (enExample)
HU (1) HUP0200917A3 (enExample)
IL (1) IL145641A0 (enExample)
MX (1) MXPA01009901A (enExample)
MY (1) MY137637A (enExample)
NO (1) NO327982B1 (enExample)
NZ (1) NZ514409A (enExample)
PL (1) PL202668B1 (enExample)
PT (1) PT1183253E (enExample)
RO (1) RO121777B1 (enExample)
RU (1) RU2265017C2 (enExample)
SA (1) SA01220045B1 (enExample)
SK (1) SK13712001A3 (enExample)
TR (1) TR200102856T1 (enExample)
TW (1) TWI291873B (enExample)
UA (1) UA75573C2 (enExample)
WO (1) WO2001057027A1 (enExample)
ZA (1) ZA200108060B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
KR100819578B1 (ko) * 2001-08-01 2008-04-04 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 Ｃ７ 에스테르 치환된 탁산
US20030082229A1 (en) * 2001-11-01 2003-05-01 Board Of Regents, The University Of Texas Systems Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
US8012950B2 (en) * 2003-08-29 2011-09-06 Wisconsin Alumni Research Foundation Method to diagnose and treat degenerative joint disease
EP1894921A3 (en) * 2003-09-25 2008-03-12 Tapestry Pharmaceuticals, Inc. 9, 10-Alpha, Alpha-Oh-Taxane analogs and methods for production thereof
PL1664033T3 (pl) * 2003-09-25 2008-04-30 Tapestry Pharmaceuticals Inc Analogi 9,10-alfa, alfa-OH-taksanu i sposoby ich wytwarzania
GT200500041A (es) 2004-03-05 2005-10-24 Taxanos con sustituyente lactiloxilo en el c7
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
WO2006042146A2 (en) * 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
CN103172662A (zh) 2004-10-25 2013-06-26 德克技术公司 作为抗肿瘤剂的异磷酰胺氮芥及其类似物的盐
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
EP2118079A1 (en) 2007-02-07 2009-11-18 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Synthetic macrocyclic compounds for treating cancer
WO2008109360A1 (en) 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
CN102942589B (zh) 2007-04-06 2016-04-20 Zio医药肿瘤学公司 异磷酰胺芥及其类似物的盐
CN102137674A (zh) 2008-07-31 2011-07-27 Zio医药肿瘤学公司 异磷酰胺芥及其类似物的合成和制剂
US8361992B2 (en) 2009-02-24 2013-01-29 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
WO2010138686A1 (en) 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
BR112012022552A8 (pt) 2010-03-10 2017-12-05 Stanford Res Inst Int uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
WO2012033601A1 (en) 2010-08-20 2012-03-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Thiosemicarbazones with mdr1 - inverse activity
EP2731626B1 (en) 2011-07-11 2018-12-19 THE UNITED STATES OF AMERICA, represented by the S Photosensitizing antibody-fluorophore conjugates
EP2854855B1 (en) 2012-05-25 2016-04-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
US9765142B2 (en) 2013-10-11 2017-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services TEM8 antibodies and their use in treatment and detection of tumors
ES2743458T5 (es) 2014-08-08 2023-06-08 Us Health Eliminación fotocontrolada de dianas in vitro e in vivo
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2019099615A1 (en) 2017-11-17 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
AU2019253681A1 (en) 2018-04-10 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation
EP3994173A1 (en) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2022109133A1 (en) 2020-11-19 2022-05-27 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
CA3210086A1 (en) 2021-01-29 2022-08-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer
WO2022232375A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
AU2023299296A1 (en) 2022-06-30 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd25-specific antibodies and uses thereof
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
SE463189B (sv) 1989-03-13 1990-10-22 Eston Joensson Preparat avsett att tillfoeras amalgamfyllningar i taender foer att daerigenom hindra eller minska avgaang av kvicksilver eller kvicksilveraanga
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
FR2679230B1 (fr) 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
SG46582A1 (en) 1991-09-23 1998-02-20 Univ Florida State 10-Desacetoxytaxol derivatives
US5227400A (en) 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5243045A (en) 1991-09-23 1993-09-07 Florida State University Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5489601A (en) * 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5714513A (en) 1991-09-23 1998-02-03 Florida State University C10 taxane derivatives and pharmaceutical compositions
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
CA2087359A1 (en) 1992-01-15 1993-07-16 Ramesh N. Patel Enzymatic processes for resolution of enantiomeric mixtures of compoundsuseful as intermediates in the preparation of taxanes
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5352806A (en) 1992-04-17 1994-10-04 Abbott Laboratories Taxol derivatives
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5319112A (en) 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
DE69333905T2 (de) 1992-12-23 2006-08-03 Bristol-Myers Squibb Co. Seitenkette tragende Taxane und deren Zwischenprodukte
IL108443A0 (en) * 1993-01-29 1994-04-12 Univ Florida State C7 taxane derivatives and pharmaceutical compositions containing them
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
IL109051A0 (en) * 1993-03-22 1994-06-24 Univ Florida State Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
PT690712E (pt) * 1993-03-22 2002-05-31 Univ Florida State Taxanos possuindo uma cadeia lateral substituida com piridilo
DE69433355T2 (de) * 1993-03-22 2004-05-27 Florida State University, Tallahassee Taxane ohne die c-9 oxo gruppe und diese enthaltende pharmazeutische präparate
WO1994029288A1 (en) 1993-06-11 1994-12-22 The Upjohn Company Δ6,7-taxols antineoplastic use and pharmaceutical compositions containing them
IL109926A (en) 1993-06-15 2000-02-29 Bristol Myers Squibb Co Methods for the preparation of taxanes and microorganisms and enzymes utilized therein
TW397866B (en) 1993-07-14 2000-07-11 Bristol Myers Squibb Co Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
FR2711369B1 (fr) 1993-10-20 1995-11-17 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions qui les contiennent.
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5414869A (en) * 1993-11-26 1995-05-16 Thomson; Margaret I. Knotless scarf and method of making same
FR2721024B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
JPH10508022A (ja) * 1994-10-28 1998-08-04 ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク タキソイド誘導体、それらの製造、およびそれらの抗腫瘍薬としての使用
TW354293B (en) 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
WO1997009979A1 (en) 1995-09-13 1997-03-20 Florida State University Radiosensitizing taxanes and their pharmaceutical preparations
US5767297A (en) 1997-02-05 1998-06-16 Ensuiko Sugar Refining Co., Ltd. Taxoid derivative and method of producing thereof
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
AU724499B2 (en) 1996-05-06 2000-09-21 Florida State University 1-deoxy baccatin III, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof
AU3122597A (en) * 1996-05-17 1997-12-09 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5811452A (en) 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
DE69729128T2 (de) * 1997-10-08 2005-04-28 Bio Research Corporation Of Yokohama, Yokohama Taxoid-derivate und verfahren zu ihrer herstellung
US6136988A (en) 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
US5964739A (en) * 1998-06-18 1999-10-12 Champ; Raynido A. Safety disposable needle structure
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
TR200103747T2 (tr) 1999-06-21 2002-04-22 Napro Biotherapeutics, Inc. C-2 Hidroksil korumalı N-Akril (2R, 3S)-3- Fenilizoserin ile aktifleştirilen esterler ve bunların üretilmesi yöntemi
WO2001025223A1 (en) 1999-10-06 2001-04-12 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
CO5280224A1 (es) * 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
NZ514073A (en) 2000-02-02 2004-02-27 Univ Florida State Res Found Taxane formulations having improved solubility
IT1319168B1 (it) 2000-03-17 2003-09-26 Indena Spa Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.

Also Published As

Publication number Publication date
DE60134094D1 (de) 2008-07-03
TR200102856T1 (tr) 2002-06-21
ES2307588T3 (es) 2008-12-01
ZA200108060B (en) 2003-12-01
EP1183253B1 (en) 2008-05-21
RU2265017C2 (ru) 2005-11-27
TWI291873B (en) 2008-01-01
NO20014759D0 (no) 2001-10-01
PT1183253E (pt) 2008-08-04
BG105967A (en) 2002-08-30
CZ298484B6 (cs) 2007-10-17
UA75573C2 (en) 2006-05-15
CA2368993C (en) 2009-10-20
NO327982B1 (no) 2009-11-02
US20040014979A1 (en) 2004-01-22
US7186849B2 (en) 2007-03-06
DK1183253T3 (da) 2008-09-22
PL202668B1 (pl) 2009-07-31
HUP0200917A3 (en) 2004-07-28
BG65279B1 (bg) 2007-11-30
GEP20043322B (en) 2003-12-10
JP2003522167A (ja) 2003-07-22
IL145641A0 (en) 2002-06-30
RO121777B1 (ro) 2008-04-30
EP1183253B8 (en) 2009-01-07
HUP0200917A2 (en) 2002-08-28
EP1183253A1 (en) 2002-03-06
MY137637A (en) 2009-02-27
US6610860B2 (en) 2003-08-26
HK1047938A1 (zh) 2003-03-14
MXPA01009901A (es) 2003-07-28
KR100784161B1 (ko) 2007-12-12
ATE396188T1 (de) 2008-06-15
AU3323901A (en) 2001-08-14
SA01220045B1 (ar) 2008-06-07
CZ20013503A3 (cs) 2002-03-13
NZ514409A (en) 2004-03-26
NO20014759L (no) 2001-11-29
US20070249708A1 (en) 2007-10-25
KR20010111583A (ko) 2001-12-19
SK13712001A3 (sk) 2002-05-09
AU776051B2 (en) 2004-08-26
WO2001057027A1 (en) 2001-08-09
CA2368993A1 (en) 2001-08-09
US20020013346A1 (en) 2002-01-31
BR0104749A (pt) 2001-12-26
HU0200917D0 (en) 2002-04-29
CO5280224A1 (es) 2003-05-30
AR030188A1 (es) 2003-08-13
PL350026A1 (en) 2002-10-21

Similar Documents

Publication Publication Date Title
CN1362955A (zh) 作为抗肿瘤剂的c7酯取代的紫杉烷
HK1047896A1 (zh) C10杂取代的乙酸基紫衫烷抗肿瘤剂
US6638973B2 (en) Taxane formulations
CN1186340C (zh) 用作抗肿瘤剂的c10碳酸酯取代的紫杉烷
US20050143446A1 (en) C7 heterosubstituted acetate taxane compositions
US6992104B2 (en) C7 carbonate taxane compositions
US6596737B2 (en) C10 carbamoyloxy substituted taxanes
CN1380882A (zh) 作为抗肿瘤剂的c10酯取代的紫杉烷
US6750245B2 (en) C7 carbamate substituted taxanes
US20050209311A1 (en) C7 lactyloxy-substituted taxanes
HK1053472B (en) C10 carbonate substituted taxanes as antitumor agents
CN1491947A (zh) C10碳酸酯取代的紫杉烷
HK1049670A (en) C10 ester substituted taxanes as antitumor agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1047938

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20020807

C20 Patent right or utility model deemed to be abandoned or is abandoned